"The objective of this research collaboration is to establish and validate RheoSwitch technology within the transgenic mouse setting through the creation of genetically modified animals," said Thomas Tillett, RheoGene's president and CEO.
The companies will also collaborate on several projects aimed at controlling delivery and regulating expression of RNAi in order to address the problems of timing and localizinf active RNAi products to various target sites in vivo.